Paving the way in botanical psychedelic drug development.
We are demonstrating the safety and efficacy of botanical psychedelic drug candidates for the first time in human clinical trials:
Our drug candidates are led through trials by Principal Investigator, Dr. Joshua Woolley, MD/Ph.D., Director of the Translational Psychedelic Research (TrPR) Program at the University of California San Francisco.
Filament has partnered with leading researchers worldwide to advance natural psychedelic research and generate revenue.
We believe that our botanical drugs could be effective in many therapeutic areas and that research on multiple indications is necessary. Our patented technology provides an attractive platform whereby third-party drug developers can leverage our IP and regulatory expertise by using Filament’s drug candidates in their clinical trials.
This provides Filament with the opportunity to obtain near-term milestone-based revenue and royalties upon commercialization.
We provide low- or no-cost study drugs to academic researchers and retain safety data for in-house programs.
This is one way in which we give back to the psychedelic research community. We also gain insights into new indications and safety data for future regulatory filings.